Compare HQY & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HQY | SYRE |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 8.5B |
| IPO Year | 2014 | 2015 |
| Metric | HQY | SYRE |
|---|---|---|
| Price | $105.86 | $103.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $115.00 | $85.08 |
| AVG Volume (30 Days) | 655.9K | ★ 861.0K |
| Earning Date | 06-03-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.69 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $229,525,000.00 | N/A |
| Revenue This Year | $8.57 | N/A |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | $128.66 | ★ N/A |
| Revenue Growth | ★ 28.68 | N/A |
| 52 Week Low | $72.76 | $14.51 |
| 52 Week High | $107.62 | $108.14 |
| Indicator | HQY | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 65.66 | 57.18 |
| Support Level | $91.60 | $92.37 |
| Resistance Level | N/A | $105.09 |
| Average True Range (ATR) | 3.01 | 5.83 |
| MACD | 0.18 | -0.24 |
| Stochastic Oscillator | 89.67 | 72.54 |
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.